MiNK Therapeutics enters amended intercompany services agreement with Agenus effective April 1, 2022

MiNK Therapeutics, Inc.

New agreement covers G&A, R&D, and shared services; MiNK pays 10% of Agenus' G&A costs.
R&D services charged at pass-through costs plus allocation of employee costs.
Shared services no charge if proportional; facility/insurance use with proportionate payment.
Either party may terminate with 60 days' notice; individual services 30 days.
Agreement retroactive to April 1, 2022, amends September 2021 agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.